If you agree to take part in this study and you are eligible for participation, you will be assigned into one of three treatment groups by the Sponsor or designee: 1. CPI-006 Intravenous (IV) injection 2. CPI-006 Intravenous (IV) injection + CPI-444 (oral) 3. CPI-006 Intravenous (IV) injection + pembrolizumab Intravenous (IV) The chances of you being assigned to any treatment group will depend upon which groups are open during your participation in the study. You or the study doctor will not be able to choose which treatment group you will be able to participate in, and you will remain on the same treatment group for your entire study participation.
CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers
OPEN TO ACCRUAL